


Form PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 13 CIP CON	SERIAL NO. 08/487,283
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		
	APPLICANT Evans et al.	
	FILING DATE 6/7/95	GROUP Art Unit: 16424

U.S. PATENT DOCUMENT

EXAMINER INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<i>mc</i>	4 5 7 8 3 3 5	3/25/86	Urdal et al.	435	68	
	4 6 8 6 1 0 0	8/11/87	Raffin et al.	424	85	
	4 8 1 6 3 9 7	3/28/89	Boss et al.	435	68	
	4 8 1 6 5 6 5	3/28/89	Honjo et al.	530	351	
	4 8 1 6 5 6 7	3/28/89	Cabilly et al.	530	387	
	4 8 4 5 1 9 3	7/4/89	Urdal et al.	530	387	
	4 8 6 7 9 3 3	8/18/89	Goers et al.	424	85.91	
	5 1 3 5 9 1 3	8/4/92	Sims et al.	514	21	
	5 1 7 3 4 2 9	10/22/92	Sindelar et al.	514	462	
	5 1 9 8 3 5 9	3/20/93	Taniguchi et al.	435	252.3	
	5 2 2 5 5 3 9	7/6/93	Winter	530	387.3	
	5 3 9 5 7 6 0	3/1/95	Smith et al.	435	240.1	
	5 5 0 6 2 4 7	4/2/96	Sindelar et al.	514	374	
	5 5 3 0 1 0 1	6/25/96	Queen et al.	530	387.3	
	5 5 8 5 0 8 9	12/17/96	Queen et al.	424	133.1	
	5 6 1 0 2 7 9	3/11/97	Brockhaus et al.	530	387.3	
	5 6 3 5 1 7 8	6/3/97	Sims et al.	424	145.1	
	5 6 9 3 7 6 1	12/2/97	Queen et al.	536	23.53	
	5 6 9 3 7 6 2	12/2/97	Queen et al.	530	387.3	
<i>mc</i>	5 8 0 8 0 2 9	9/15/98	Brockhaus et al.	536	23.5	
	5 8 5 9 2 0 5	1/12/99	Adair et al.	530	387.3	

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
					YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

See Attached	
EXAMINER <i>Gamber</i> 11/13/00	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner InitialOTHER ART

M

AMES et al., "Isolation of neutralizing anti-C5a monoclonal antibodies from a filamentous phage monovalent fab display library" J. Immunol. 152:4572-4581, 1994.

AUDA et al., "Measurement of complement activation products in patients with chronic rheumatic diseases" Rheumatol Int 10:185-189, 1990 .

BAKER et al., "Depletion of C6 prevents development of proteinuria in experimental membranous nephropathy in rats" Am J Path. 135:185-194, 1989.

BHAKDI et al., "Electroimmunoassay-immunoblotting (EIA-IB) for utilization of monoclonal antibodies in quantitative immunoelectrophoresis: the method and its applications" J Immunol Methods, 80:25-32, 1985.

BIESECKER et al., "The release of C5a in complement-activated serum does not require C6" J Immunol, 143:1228-1232, 1989.

COCHRANE et al., "A role of polymorphonuclear leukocytes and complement in nephrotoxic nephritis" J Exp Med, 122:99-116, 1965.

COUSER et al., "C6 depletion reduces proteinuria in experimental nephropathy induced by a nonglomerular antigen" J Am Soc Nephrol, 2:894-901, 1991.

COUSER et al., "Complement and the direct mediation of immune glomerular injury: A new perspective" Kidney Internat, 28:879-890, 1985.

COUSER et al., "Role of C5b-9 in experimental membranous nephropathy" Nephrol Dial Transplant, Suppl 1:25-31, 1992 .

DALMASSO et al., "Complement channels in membranes: inhibition with a monoclonal antibody to a neoantigen of polymerized C9" Biochem Biophys Res Commun, 125:1013-1019, 1984.

DISCIPIO et al., "The activation of human complement component C5 by a fluid phase C5 convertase." 258(17), 10629-10636, 1983 .

DISCIPIO et al., "The conversion of human complement component C5 into fragment C5b by the alternative-pathway C5 convertase" Biochem J, 199:497-504, 1981.

DISCIPIO, "Formation and structure of the C5b-7 complex of the lytic pathway of complement" J Biol Chem 267:17087-17094, 1992.

FALK and JENNETTE, "Immune complex induced glomerular lesions in C5 sufficient and deficient mice" Kidney Internat, 30:678-686, 1986.

FLOEGE et al., "Markers of complement-dependent and complement-independent glomerular visceral epithelial cell injury in vivo" Lab Invest, 67:486-497, 1992.

FREI et al., "Generation of a monoclonal antibody to mouse C5 application in an ELISA assay for detection of anti-C5 antibodies" Mol Cell Probes, 1:141-149, 1987.

GARRAD et al., "Synthesis of C3, C5, C6, C7, C8, and C9 by human fibroblast."

M

GAMBER 11/13/00

Scand J. Immunol 32(5): 555-560, 1990 .

16
GICLAS et al., "Preparation and characterization of monoclonal antibodies against the fifth component of rabbit complement (C5)" J Immunol Meth 105:201-209, 1987.

GOLDMAN and GOLDMAN, "Antibody-induced suppression of the fifth component of complement in mice" J Immunol, 120:400-407, 1978.

GROGGER et al., "Role of the terminal complement pathway in experimental membranous nephropathy in the rabbit" J Clin Invest, 72:1948-1957, 1983.

HONG et al., "An anticomplement agent, K-76 monocarboxylic acid: Its site and mechanism of inhibition of the complement activation cascade." J. Immunol 122:2418-2433, 1979

HUGO et al., "Monoclonal antibodies against neoantigens of the terminal C5b-9 complex of human complement" BioScience Rep, 5:649-658, 1985.

HUGO et al., "Sensitive ELISA for quantitating the terminal membrane C5b-9 and fluid-phase SC5b-9 complex of human complement" J Immunol Methods 99:243-251 1987.

INOUE, "C5 neoepitopes appearing during activation." Complement Inflamm 6(3):219-222, 1989

JENNETTE et al., "Amelioration of immune complex-mediated glomerulonephritis by synthetic protease inhibitors" Am J Path, 127:499-506, 1987.

JONES et al., "Replacing the complementarity-determining regions in a human antibody with those from a mouse." Nature, 321: 522-525, 1986

KITAMURA et al., "The activation of C5 in the fluid phase and in the absence of C3 through the classical pathway of the complement system." Immunology 58(3): 459-465, 1986

KLOS et al., "Detection of native human complement components C3 and C5 and their primary activation peptides C3a and C5a (anaphylatoxic peptides) by ELISAs with monoclonal antibodies" J Immunol Methods 111:241-252, 1988.

KNICKER and COCHRANE, "Pathogenic factors in vascular lesions of experimental serum sickness" J Exp Med, 122:83-97, 1965.

KOLB and MULLER-EBERHARD, "The Membrane Attack Mechanism of Complement" J Exper Med, 141:724-735, 1975.

MINTA and MAN, "Cleavage of Human C5 By Trypsin: Characterization of the Digestion Products by Gel Electrophoresis" J Immunol, 119:1597-1602, 1977.

MOLLNES et al., "Identification of a human C5 β -chain epitope exposed in the native complement component but concealed in the SC5b-9 complex" Scand J Immunol, 28:307-312, 1988.

2
MOLLNES et al., "Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex." Scand J. Immunol, 22(2): 197-202, 1985

PHILIP GIMDEL 11/13/00

MONTZ et al., "Regulation of the human autologous T cell proliferation by endogenously generated C5a" Cell Immunol, 127:337-351, 1990.

MOONGKARNDI et al., "Monoclonal antibodies against the fifth component of human complement" Immunobiol 162:397, 1982 .

MOONGKARNDI et al., "Immunological and functional properties of two monoclonal antibodies against human C5." Immunobiol 165:323, 1983 .

MORRISON, "In vitro antibodies strategies for production and application" Ann Rev Immunol 10:239-265, 1992 .

MORGAN, "Clinical complementology recent progress and future trends." EPO J. Clinical Invesg. 24: 219-228, 1994 .

MORGAN et al., "Inhibition of complement-induced [14C] sucrose release by intracellular and extracellular monoclonal antibodies to C9: evidence that C9 is a transmembrane protein." Biochem Biophys Res Commun, 118(2):616-622, 1984 .

PASSWELL et al., "Local extrahepatic expression of complement genes C3, factor B, C2, and C4 is increased in murine lupus nephritis" J Clin Invest, 82:1676-1684, 1988.

PEAKE et al., "Differences in the metabolism of C4 in patients with complement activation." Clin Exp Immunol 78:49-53, 1989 .

PEREZ et al., "Complement (C5)-derived chemotactic activity in serum from patients with pancreatitis" J Lab Clin Med, 101:123-129, 1983.

PEREZ et al., "Radioimmuno-electrophoresis, a sensitive method of detecting cleavage of the fifth component of human complement (C5)" J Immunol Methods, 56:55-62, 1983.

REED et al., "Synthesis of complement component C5 by human B and T lymphoblastoid cell lines" Immunogenetics, 31:145-151, 1990.

RIECHMANN et al., "Reshaping human antibodies for therapy." Nature, 332: 323-327, 1988 .

RINDER et al., "Blockade of C5 and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation." J. Clinical Invesg. 96(3): 1564-1572 .

RODRIGUES et al., "Engineering fab' fragments for efficient F(ab)₂ formation in escherichia coli and for improved in vivo stability." J. Immunology, 151(12): 6954-6961, 1993 .

ROTTINI et al., "Monoclonal antibodies as probes to investigate the molecular changes of C5 associated with the different stability of the molecule on sheep erythrocytes and *Escherichia coli* 0111:B4" J. Immunol 146:643-647, 1991.

SALANT et al., "A new role for complement in experimental membranous nephropathy in rats" J Clin Invest, 66:1339-1350, 1980.

SCHRIJVER et al., "Anti-GBM nephritis in the mouse: role of granulocytes in the heterologous phase" Kidney Internat, 38:86-95, 1990.

Gsm1352 11/13/00

08/487283

ANTWITL641

SCHRIJVER et al., "Antiglomerular basement membrane nephritis in the mouse" Lab Invest, 59:484-491, 1988.

SEEGER et al., "Noncytolytic terminal complement complexes may serve as calcium gates to elicit leukotriene B4 generation in human polymorphonuclear leukocytes." J. Immunol, 137(4): 1286-1293, 1986 .

STAHL et al., "Role of granulocytes and C5 in myocardial response to zymosan-activated serum." Am J. Physiol, 261(1 Pt2): H29-H37, 1991 .

SUNDSMO, "Leukocyte complement: a possible role for C5 in lymphocyte stimulation" J Immunol, 131:886-891, 1983.

TAKEDA et al., "Rapid and simple measurement of human C5a-des-Arg level in plasma or serum using monoclonal antibodies" J Immunol Methods, 101:265-270, 1987.

UNANUE and DIXON, "Participation of complement in nephrotoxic nephritis" J Exp Med, 119:965-982, 1964.

VOGT et al., "'Inactivated' third component of complement (C3b-like C3; C3i) acquires C5 binding capacity and supports C5 activation upon covalent fixation to a solid surface" Complement, 1:87-96, 1984.

VOGT et al., "Non-enzymic activation of the fifth component of human complement. by oxygen radicals. some properties of the activation product. C5b-like C5" Mol Immunol 26(12): 1133-1142, 1989.

WETSEL and KOLB, "Complement-independent activation of the fifth component (C5) of human complement: limited trypsin digestion resulting in the expression of biologic activity" J Immunol 128:2209-2216, 1982.

WURZNER et al., "Inhibition of terminal complement complex formation and cell lysis by monoclonal antibodies" Complement Inflamm, 8:328-340, 1991.

Gamber 11/3/00